BioInvent International AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BOVNF research report →
Companywww.bioinvent.com
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma.
- CEO
- Martin Welschof
- IPO
- 2013
- Employees
- 114
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $216.40M
- P/E
- -5.07
- P/S
- 7.79
- P/B
- 3.87
- EV/EBITDA
- -4.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.48%
- Op Margin
- -161.05%
- Net Margin
- -153.98%
- ROE
- -53.88%
- ROIC
- -78.78%
Growth & Income
- Revenue
- $225.93M · 405.59%
- Net Income
- $-332,023,010 · 22.67%
- EPS
- $-5.07 · 22.36%
- Op Income
- $-350,509,523
- FCF YoY
- 34.86%
Performance & Tape
- 52W High
- $4.70
- 52W Low
- $3.29
- 50D MA
- $3.29
- 200D MA
- $3.29
- Beta
- -0.05
- Avg Volume
- 2.35K
Get TickerSpark's AI analysis on BOVNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BOVNF Coverage
We haven't published any research on BOVNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BOVNF Report →